InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by DeLong Mark Jeffrey, Chief Business & Strat Officer. Officer active across 2 companies, notably Apellis Pharmaceuticals, Inc.. Cumulatively, 21 disclosures have been recorded. The latest transaction was filed on 16 June 2022 — Levée d'options. Regulator: SEC (Form 4). The full history is openly available.
Declarations21 total
114,591 shares
Common Stock
SEC:0001193125-26-224597·
114,591 shares
Common Stock
SEC:0001193125-26-224597:0·
€131,31910,000 shares@ €13.13190.0025% mcap29.0% of flow
Common Stock
SEC:0001127602-22-017896:0·
€100,1307,000 shares@ €14.30430.0019% mcap22.1% of flow
Common Stock
SEC:0001127602-22-012442:0·
€11,180271 shares@ €41.25540.0002% mcap2.5% of flow
Common Stock
SEC:0001127602-22-004770:0·
013,913 shares0
Common Stock
SEC:0000899243-22-005089·
013,913 shares0
Common Stock
SEC:0000899243-22-005089:0·
€15,025434 shares@ €34.61910.0003% mcap16.2% of flow
Common Stock
SEC:0001127602-22-002816·
€15,025434 shares@ €34.61910.0003% mcap3.3% of flow
Common Stock
SEC:0001127602-22-002816:0·
010,592 shares0
Common Stock
SEC:0001127602-22-002057:0·
010,592 shares0
Common Stock
SEC:0001127602-22-002057·
0882 shares0
Common Stock
SEC:0001127602-21-027697·
0882 shares0
Common Stock
SEC:0001127602-21-027697:0·
€13,1611,000 shares@ €13.16070.0003% mcap14.2% of flow
Common Stock
SEC:0001127602-21-022382·
€13,1611,000 shares@ €13.16070.0003% mcap2.9% of flow
Common Stock
SEC:0001127602-21-022382:0·
€13,1391,000 shares@ €13.13940.0003% mcap14.2% of flow
Common Stock
SEC:0001127602-21-022141·
€13,1391,000 shares@ €13.13940.0003% mcap2.9% of flow
Common Stock
SEC:0001127602-21-022141:0·
€51,1914,000 shares@ €12.79780.0010% mcap55.3% of flow
Common Stock
SEC:0001127602-21-020052·
€51,1914,000 shares@ €12.79780.0010% mcap11.3% of flow
Common Stock
SEC:0001127602-21-020052:0·
€25,3932,000 shares@ €12.69630.0008% mcap100.0% of flow
Common Stock
SEC:0001127602-21-017369·
€25,3932,000 shares@ €12.69630.0005% mcap5.6% of flow
Common Stock
SEC:0001127602-21-017369:0·
21 of 21 declarations
About DeLong Mark Jeffrey
Mark Jeffrey DeLong is the Chief Business & Strategy Officer at Apellis Pharmaceuticals, Inc.
